Tests nucresiran against placebo in people with transthyretin amyloidosis heart disease
Tests nucresiran against a placebo in adults with heart disease from transthyretin amyloidosis.
Plain-language title generated from the registry record
Registry title: TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
Key facts
- Where
- Basel, Bern, Geneva, Lucerne, and Sankt Gallen, SwitzerlandSee the 5 sites
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 85 years old?
Source: NCT07052903, who can take part
Where in Switzerland
- BaselBasel, SwitzerlandTaking people
- BernBern, SwitzerlandTaking people
- GenevaGeneva, SwitzerlandTaking people
- LucerneLucerne, SwitzerlandTaking people
- Sankt GallenSankt Gallen, SwitzerlandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Alnylam Pharmaceuticals
- Trial code
- NCT07052903EU 2024-519917-72-00
- Record updated
- 20 October 2026
- Original description
The purpose of this study is to:Read full original descriptionShow less
TRITON-CM: A Phase 3 Global, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Transthyretin-Mediated Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)
The purpose of this study is to:
* Evaluate the efficacy of nucresiran compared to placebo on reducing all-cause mortality and cardiovascular (CV) events * Evaluate the efficacy of nucresiran compared to placebo on additional assessments of CV events and/or death * Evaluate the efficacy of nucresiran compared to placebo on patient-reported health status and health-related quality of life
Inclusion: Has documented diagnosis of ATTR amyloidosis with cardiomyopathy including those with hereditary ATTR (hATTR) or wild-type ATTR (wATTR) amyloidosis; Has medical history of heart failure (HF) with at least 1 prior hospitalization for HF or signs and symptoms that require treatment with a diuretic; Has screening N-terminal prohormone B-type natriuretic peptide (NT-proBNP) >300 ng/L and <8500 ng/L; In patients with permanent or persistent atrial fibrillation, screening NT-proBNP >600 ng/L and <8500 ng/L; Patients may be receiving approved TTR stabilizers for ATTR amyloidosis (eg, tafamidis, acoramidis) and may be receiving background therapy for HF at the discretion of the Investigator.
Exclusion: Has received prior or currently receiving TTR-lowering therapy; Has New York Heart Association (NYHA) Class IV HF; or NYHA Class III heart failure AND ATTR Amyloidosis Disease Stage 3; Has an estimated glomerular filtration rate (eGFR) of <30 mL/min/1.73m\^2 at screening; Has a polyneuropathy disability (PND) Score IIIa, IIIb, or IV.